Browsing by Author "Yılmaz, Vuslat"
Now showing items 1-7 of 7
-
Assessment of short-term ocrelizumab treatment impact on regulatory immune cell subsets through intracellular cytokine measurement in patients with multiple sclerosis
Akbayır, Ece; Karaaslan, Zerrin; Türkoğlu, Recai; Kızılay, Tuğçe; Yıldız, Ruziye Erol; Özkan-Yaşargün, Duygu; Yılmaz, Vuslat; Tüzün, Erdem (SAGE PUBLICATIONS LTD, 2025)Meeting Abstract -
B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis
Akbayır, Ece; Kızılay, Tuğçe; Erol, Ruziye; Özkan Yaşargün, Duygu; Tüzün, Erdem; Yılmaz, Vuslat; Türkoğlu, Recai (INT INST ANTICANCER RESEARCH, 2025)Background/Aim: Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment ... -
Baseline eronufilmniaet light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis
Yıldız, Ruziye Erol; Akbayır, Ece; Kızılay, Tuğçe; Ersöz, Ayça Simay; Yaşargün, Duygu Özkan; Süer, Devran; Yılmaz, Vuslat; Tüzün, Erdem; Türkoğlu, Recai (Tubitak Scientific & Technological Research Council Turkey, 2025)Background/aim: Patients with multiple sclerosis (MS) may present with a rapidly disabling clinical course in the first few years of disease. It is imperative to find biomarkers to predict patients with aggressive MS (AMS) ... -
Effect of immunotherapy on seizure severity and spike-wave index in epileptic encephalopathy with spike-wave activation in sleep: The value of EEG spikes in monitoring treatment response
Topaloğlu, Pınar; Dörtkol, Ozan; Emekli, Serkan; Yazıcı, Ayşe Deniz Elmalı; Tüzün, Erdem; Yılmaz, Vuslat; Küçükali, Cem İsmail; Öz, Fırat; Savaş, Merve; Beğen, Senanur Kahraman; Tarhan, Güllü; Bebek, Nerses; Yapıcı, Zuhal (ELSEVIER, 2026)Objective: To evaluate the electrophysiological and clinical effects of intravenous immunoglobulin (IVIg) therapy in children with epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) and developmental ... -
Effects of immune modulatory treatment on language and psychiatric profile in patients with electrical status epilepticus in sleep (ESES)
Emekli, Ahmed Serkan; Dörtkol, Şevket Ozan; Şavaş, Merve; Öz, Fırat; İşcen, Pınar; Topaloğlu, Pınar; Tarhan, Güllü; Soylu, Selen; Yılmaz, Vuslat; Küçükali, Cem Ismail; Tüzün, Erdem; Yapıcı, Zuhal (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2025)Electrical status epilepticus in sleep (ESES) is an electrographic pattern associated with cognitive impairment. Our study aimed to prospectively evaluate the psychiatric findings and language skills in patients diagnosed ... -
Impact of Intravenous Immunoglobulin on Neuroinflammation Markers in Patients With Electrical Status Epilepticus During Slow Sleep
Koral, Gizem; Tüzün, Erdem; Emekli, Ahmed Serkan; Dörtkol, Şevket Ozan; Savaş, Merve; Öz, Fırat; Soylu, Selen; Yüceer-Korkmaz, Hande; Topaloğlu, Pınar; Yılmaz, Vuslat (INT INST ANTICANCER RESEARCH, 2026)Conclusion: IVIg treatment dampens the neuroinflammatory response and thus immune-modulatory treatment in combination with ASD may contribute to the improvement of ESES symptoms. CXCL13, HMGB1 and IL-1(3 may serve as markers ... -
Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study
Şişman, Aysel Büşra; Savaş, Merve; Koral, Gizem; Bayar, Muhammet Duran; Yıldız, Oğuz; Mutlu, Aytul; Yılmaz, Vuslat; Tüzün, Erdem; Çokar, Özlem (LITERATURA MEDICA, 2025)Background and purpose-The role of synaptic dysfunction in focal epilepsy of unknown cause is not well understood. Neurogranin is a post-synaptic protein used as a biomarker of synaptic disintegration in patients with ...
